Regulatory Alignment Between the United Kingdom and Europe Post Brexit
Jefferys D.
RDD Europe 2019. Volume 1, 2019: 133-136.
Abstract:
At RDD Europe 2017, the impact of Brexit on the licensing of pharmaceutical products in the United Kingdom (UK) and within the European regulatory system was discussed. Article 50 of the Lisbon Treaty was triggered on March 29, 2017 which set in motion a two-year countdown to negotiate an exit deal.
Two years on, at the time of writing this summary (March 14, 2019) there still remains considerable uncertainty about how the UK will leave the European Union. The presentation at RDD Europe 2019 will provide an up-to-date picture concerning the regulation of medicines and devices and provide a forward view as to what may happen over the next five years.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
